The blood–brain barrier (BBB)
acts as a physical/biochemical
barrier that protects brain parenchyma from potential hazards exerted
by different xenobiotics found in the systemic circulation. This barrier
is created by “a lipophilic gate” as well as a series
of highly organized influx/efflux mechanisms. The BBB bottleneck adversely
affects the efficacy of chemotherapeutic agents in treating different
CNS malignancies such as glioblastoma, an aggressive type of cancer
affecting the brain. In the present study, mesoporous silica nanoparticles
(MSNs) were conjugated with the transactivator of transcription (TAT)
peptide, a cell-penetrating peptide, to produce MSN-NH-TAT with the
aim of improving methotrexate (MTX) penetration into the brain. The
TAT-modified nanosystem was characterized by Fourier transform infrared
spectrometry (FTIR), field emission scanning electron microscopy (FE-SEM),
transmission electron microscopy (TEM), atomic force microscopy (AFM),
dynamic light scattering (DLS), and N2 adsorption–desorption
analysis. In vitro hemolysis and cell viability studies
confirmed the biocompatibility of the MSN-based nanocarriers. In addition, in vivo studies showed that the MTX-loaded MSN-NH-TAT improved
brain-to-plasma concentration ratio, brain uptake clearance, and the
drug’s blood terminal half-life, compared with the use of free
MTX. Taken together, the results of the present study indicate that
MSN functionalization with TAT is crucial for delivery of MTX into
the brain. The present nanosystem represents a promising alternative
drug carrier to deliver MTX into the brain via overcoming the BBB.